Illumina (ILMN) Tops Q3 EPS by 25c

Illumina (NASDAQ: ILMN) reported Q3 EPS of $1.02, $0.25 better than the analyst estimate of $0.77. Revenue for the quarter came in at $794 million versus the consensus estimate of $715.91 million.

“Our business accelerated in the third quarter with sequencing consumable revenue growing 29% from the second quarter,” said Francis deSouza, Chief Executive Officer. “We’re also making progress incorporating genomics into the standard of care in non-invasive pre-natal testing, oncology therapy selection, and genetic disease diagnosis. Looking forward, we believe our planned acquisition of GRAIL will catalyze a new era of early cancer detection, transforming cancer survivability and opening up the largest clinical application of genomics we’ve seen.”

GUIDANCE:

As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic.

For earnings history and earnings-related data on Illumina (ILMN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance